Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections

INTRODUCTION: Childhood respiratory syncytial virus (RSV) infection is a global phenomenon that can lead to fatal respiratory illness. Palivizumab is a drug that is routinely used in affluent countries as a prophylaxis against RSV infection; nevertheless, breakthrough infections are often reported....

Descripción completa

Detalles Bibliográficos
Autores principales: Jun, Shelly, Sebastianski, Meghan, Featherstone, Robin, Robinson, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Paediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661690/
https://www.ncbi.nlm.nih.gov/pubmed/31340973
http://dx.doi.org/10.1136/bmjopen-2019-029832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661690/
https://www.ncbi.nlm.nih.gov/pubmed/31340973
http://dx.doi.org/10.1136/bmjopen-2019-029832

Ejemplares similares